• Argirios E Tsantes, Iraklis Tsangaris, Stefanos Bonovas, Petros Kopterides, Evdoxia Rapti, Ioanna Dimopoulou, Christos Markatos, Stylianos Orfanos, Apostolos Armaganidis, and Anthi Travlou.
• Laboratory of Haematology & Blood Bank Unit, Attikon University General Hospital, Medical School, University of Athens, 1 Rimini Str., Athens, Greece. atsantes@yahoo.com
• Blood Coagul. Fibrinolysis. 2010 Mar 1;21(2):175-81.

AbstractGenetic variants of hemostatic factors leading to prothrombotic phenotypes of hypercoagulability and hypofibrinolysis might affect prognosis of septic critically ill patients. Our aim was to evaluate the effect of four hemostatic genetic variants, namely fibrinogen-beta-455G/A, factor XIII (FXIII) V34L, plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphisms and factor V Leiden (FVL) mutation on survival of critically ill patients with severe sepsis or septic shock. A prospective, observational study in an 18-bed general ICU included 73 patients with severe sepsis or septic shock. Epidemiological, laboratory data and comorbidities along with severity scores were recorded. Genotyping for fibrinogen-beta-455G/A, FXIII V34L and PAI-1 4G/5G polymorphism and FVL mutation was carried out in all patients. The primary outcomes were the 28-day and the 90-day survival. Age, septic shock, severity indexes, prior steroid use and arterial pH were identified as predictors of the 28-day and 90-day survival in both the univariate and the multivariate models. On the contrary, none of the examined polymorphisms was found to significantly affect either the 28-day or the 90-day survival. Our data suggest that the importance of these hemostatic polymorphisms as predictors of the prognosis of sepsis in critically ill patients is probably very small.

30 keywords...

hide…